← Eichor
Study identifier: NCT07449754 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Belvarafenib in Combination With Cobimetinib in Patients With Locally Advanced or Metastatic NRAS-Mutant Melanoma

Condition: Advanced or Metastatic Melanoma  ·  Sponsor: Hanmi Pharmaceutical Company Limited

PhasePhase 2
Planned participants45
Who can joinAll sexes, 19 Years to no upper limit
Healthy volunteersNo

About this study

This is a Phase 2 open-label, multicenter, single-arm study evaluating the combination of Belvarafenib and Cobimetinib in patients with locally advanced or metastatic melanoma with NRAS mutations. The study plans to assess ORR, DCR, DOR, TTP, PFS, OS and safety of the participating subjects. Treatment cycles for all subjects will be 28 days in duration and Belvarafenib and Cobimetinib will be administered orally in combination.

This description comes directly from the study's public registry record.

Talk to the study team

Young Su (Bobby) Noh  ·  82-2-410-9277  ·  63forever@hanmi.co.kr

Always discuss trial participation with your own doctor first.

Locations (10)

Seoul National University Bundang HospitalSeongnam-si, Gyeonggi-do, South KoreaNot Yet Recruiting
Chonnam National University Hwasun HospitalHwasun, Jeollanam-do, South KoreaNot Yet Recruiting
Dong-A University Medical CenterBusan, South KoreaRecruiting
Kyungpook National University Chilgok HospitalDaegu, South KoreaNot Yet Recruiting
Chungnam National University HospitalDaejeon, South KoreaNot Yet Recruiting
Seoul National University HospitalSeoul, South KoreaNot Yet Recruiting
Severance HospitalSeoul, South KoreaRecruiting
Asan Medical CenterSeoul, South KoreaRecruiting
Samsung Medical CenterSeoul, South KoreaRecruiting
Korea University Guro HospitalSeoul, South KoreaNot Yet Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07449754